• 1. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 2. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Research Brief on 3-Methylene Simvastatin Impurity (79902-62-8): Recent Advances and Implications

The chemical compound with CAS number 79902-62-8, known as 3-Methylene Simvastatin Impurity, has garnered significant attention in the field of pharmaceutical chemistry and drug development. This impurity is structurally related to simvastatin, a widely prescribed cholesterol-lowering medication. Recent studies have focused on understanding its formation, characterization, and potential impact on drug safety and efficacy. The identification and control of such impurities are critical in ensuring the quality of pharmaceutical products, making this an area of active research.

Recent advancements in analytical techniques, such as high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS), have enabled more precise detection and quantification of 3-Methylene Simvastatin Impurity. A study published in the Journal of Pharmaceutical and Biomedical Analysis (2023) demonstrated the use of ultra-high-performance liquid chromatography (UHPLC) to achieve a detection limit of 0.01% for this impurity in simvastatin formulations. This level of sensitivity is crucial for compliance with regulatory standards set by agencies like the FDA and EMA.

Another key area of research involves the synthesis and characterization of 3-Methylene Simvastatin Impurity to better understand its chemical properties and behavior. A 2022 study in Organic Process Research & Development detailed a novel synthetic route for this impurity, which provided insights into its stability under various conditions. The findings suggested that the impurity is prone to degradation under acidic conditions, which has implications for the storage and formulation of simvastatin-based drugs.

The toxicological profile of 3-Methylene Simvastatin Impurity has also been a subject of investigation. In vitro studies using human hepatocyte models have indicated that the impurity exhibits minimal cytotoxicity at concentrations typically found in pharmaceutical formulations. However, further in vivo studies are needed to fully assess its safety. These findings are particularly relevant for regulatory submissions and quality control processes in the pharmaceutical industry.

In conclusion, the ongoing research on 3-Methylene Simvastatin Impurity (79902-62-8) underscores its importance in pharmaceutical quality assurance. Advances in analytical methodologies, synthetic chemistry, and toxicology have provided valuable insights, but gaps remain in understanding its long-term effects. Future studies should focus on comprehensive risk assessments and the development of robust mitigation strategies to ensure patient safety and regulatory compliance.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)